Minireviews
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2015; 21(29): 8811-8816
Published online Aug 7, 2015. doi: 10.3748/wjg.v21.i29.8811
Chemotherapy beyond second-line in advanced gastric cancer
Sung Min Kim, Se Hoon Park
Sung Min Kim, Se Hoon Park, Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University Samsung Medical Center, Seoul 135-710, South Korea
Author contributions: Kim SM performed the research; Park SH designed the research and wrote the paper.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Se Hoon Park, MD, Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University Samsung Medical Center, Seoul 135-710, South Korea. hematoma@skku.edu
Telephone: +82-2-34103459 Fax: +82-2-34101754
Received: January 22, 2015
Peer-review started: January 24, 2015
First decision: March 10, 2015
Revised: March 23, 2015
Accepted: June 16, 2015
Article in press: June 16, 2015
Published online: August 7, 2015
Core Tip

Core tip: There no evidence to date that chemotherapy beyond second-line has a beneficial effect in patients with gastric cancer. The impact of third- and subsequent lines of chemotherapy on survival and quality of life is the subject of this review.